Sampling useful three-dimensional molecular structures along with their most favorable conformations is a key challenge in drug discovery. Current state-of-the-art 3D de-novo design flow matching or diffusion-based models are limited to generating a single conformation. However, the conformational landscape of a molecule determines its observable properties and how tightly it is able to bind to a given protein target. By generating a representative set of low-energy conformers, we can more directly assess these properties and potentially improve the ability to generate molecules with desired thermodynamic observables. Towards this aim, we propose FlexiFlow, a novel architecture that extends flow-matching models, allowing for the joint sampling of molecules along with multiple conformations while preserving both equivariance and permutation invariance. We demonstrate the effectiveness of our approach on the QM9 and GEOM Drugs datasets, achieving state-of-the-art results in molecular generation tasks. Our results show that FlexiFlow can generate valid, unstrained, unique, and novel molecules with high fidelity to the training data distribution, while also capturing the conformational diversity of molecules. Moreover, we show that our model can generate conformational ensembles that provide similar coverage to state-of-the-art physics-based methods at a fraction of the inference time. Finally, FlexiFlow can be successfully transferred to the protein-conditioned ligand generation task, even when the dataset contains only static pockets without accompanying conformations.

Structure-based drug design (SBDD), aiming to generate 3D molecules with high binding affinity toward target proteins, is a vital approach in novel drug discovery. Although recent generative models have shown great potential, they suffer from unstable probability dynamics and mismatch between generated molecule size and the protein pockets geometry, resulting in inconsistent quality and off-target effects. We propose PAFlow, a novel target-aware molecular generation model featuring prior interaction guidance and a learnable atom number predictor. PAFlow adopts the efficient flow matching framework to model the generation process and constructs a new form of conditional flow matching for discrete atom types. A protein-ligand interaction predictor is incorporated to guide the vector field toward higher-affinity regions during generation, while an atom number predictor based on protein pocket information is designed to better align generated molecule size with target geometry. Extensive experiments on the CrossDocked2020 benchmark show that PAFlow achieves a new state-of-the-art in binding affinity (up to -8.31 Avg. Vina Score), simultaneously maintains favorable molecular properties.

However, existing models primarily focus on learning the chemical distribution of all drug candidates, which lacks effective steerability on the chemical quality of model generations.

Recently, machine learning has made a significant impact on de novo drug design. However, current approaches to creating novel molecules conditioned on a target protein typically rely on generating molecules directly in the 3D conformational space, which are often slow and overly complex. In this work, we propose SOLD (SELFIES-based Objective-driven Latent Diffusion), a novel latent diffusion model that generates molecules in a latent space derived from 1D SELFIES strings and conditioned on a target protein. In the process, we also train an innovative SELFIES transformer and propose a new way to balance losses when training multi-task machine learning models.Our model generates high-affinity molecules for the target protein in a simple and efficient way, while also leaving room for future improvements through the addition of more data.

Bayesian Flow Networks (BFNs) have recently shown impressive performance across diverse chemical tasks, with their success often ascribed to the paradigm of modeling in a low-variance parameter space. However, the Bayesian inference-based strategy imposes limitations on designing more flexible distribution transformation pathways, making it challenging to adapt to diverse data distributions and varied task requirements. Furthermore, the potential for simpler, more efficient parameter-space-based models is unexplored. To address this, we propose a novel Parameter Interpolation Flow model (named PIF) with detailed theoretical foundation, training, and inference procedures. We then develop MolPIF for structure-based drug design, demonstrating its superior performance across diverse metrics compared to baselines. This work validates the effectiveness of parameter-space-based generative modeling paradigm for molecules and offers new perspectives for model design.

We introduce FLOWR, a novel structure-based framework for the generation and optimization of three-dimensional ligands. FLOWR integrates continuous and categorical flow matching with equivariant optimal transport, enhanced by an efficient protein pocket conditioning. Alongside FLOWR, we present SPINDR, a thoroughly curated dataset comprising ligand-pocket co-crystal complexes specifically designed to address existing data quality issues. Empirical evaluations demonstrate that FLOWR surpasses current state-of-the-art diffusion- and flow-based methods in terms of PoseBusters-validity, pose accuracy, and interaction recovery, while offering a significant inference speedup, achieving up to 70-fold faster performance. In addition, we introduce FLOWR:multi, a highly accurate multi-purpose model allowing for the targeted sampling of novel ligands that adhere to predefined interaction profiles and chemical substructures for fragment-based design without the need of re-training or any re-sampling strategies

In recent years, deep learning techniques have made significant strides in molecular generation for specific targets, driving advancements in drug discovery. However, existing molecular generation methods present significant limitations: those operating at the atomic level often lack synthetic feasibility, drug-likeness, and interpretability, while fragment-based approaches frequently overlook comprehensive factors that influence protein-molecule interactions. To address these challenges, we propose a novel fragment-based molecular generation framework tailored for specific proteins. Our method begins by constructing a protein subpocket and molecular arm concept-based neural network, which systematically integrates interaction force information and geometric complementarity to sample molecular arms for specific protein subpockets. Subsequently, we introduce a diffusion model to generate molecular backbones that connect these arms, ensuring structural integrity and chemical diversity. Our approach significantly improves synthetic feasibility and binding affinity, with a 4% increase in drug-likeness and a 6% improvement in synthetic feasibility. Furthermore, by integrating explicit interaction data through a concept-based model, our framework enhances interpretability, offering valuable insights into the molecular design process.

The dynamic nature of proteins, influenced by ligand interactions, is essential for comprehending protein function and progressing drug discovery. Traditional structure-based drug design (SBDD) approaches typically target binding sites with rigid structures, limiting their practical application in drug development. While molecular dynamics simulation can theoretically capture all the biologically relevant conformations, the transition rate is dictated by the intrinsic energy barrier between them, making the sampling process computationally expensive. To overcome the aforementioned challenges, we propose to use generative modeling for SBDD considering conformational changes of protein pockets. We curate a dataset of apo and multiple holo states of protein-ligand complexes, simulated by molecular dynamics, and propose a full-atom flow model (and a stochastic version), named DynamicFlow, that learns to transform apo pockets and noisy ligands into holo pockets and corresponding 3D ligand molecules. Additionally, the resultant holo-like states provide superior inputs for traditional SBDD approaches, playing a significant role in practical drug discovery. Modern deep learning is advancing several areas within drug discovery. Notably, among these, structure-based drug design (SBDD) (Anderson, 2003) emerges as a particularly significant and challenging domain. SBDD aims to discover drug-like ligand molecules specifically tailored to target binding sites. However, the complexity of chemical space and the dynamic nature of molecule conformations make traditional methods such as high throughput and virtual screenings inefficient. Additionally, relying on compound databases limits the diversity of identified molecules. Thus, deep generative models, such as autoregressive models (Luo et al., 2021; Peng et al., 2022) and diffusion models (Guan et al., 2023; Schneuing et al., 2022), have been introduced as a tool for de novo 3D ligand molecule design based on binding pockets, significantly transforming research paradigms. However, most SBDD methods based on deep generative models assume that proteins are rigid (Peng et al., 2022; Guan et al., 2024). However, the dynamic behavior of proteins is crucial for practical drug discovery (Karelina et al., 2023; Boehr et al., 2009). Thermodynamic fluctuations result in proteins existing as an ensemble of various conformational states, and such states may interact with different drug molecules. During binding, the protein's structure may undergo fine-tuning, adopting different conformations to optimize its interaction with the drug, a phenomenon referred to as induced fit (Sherman et al., 2006).

Structure-based molecule optimization (SBMO) aims to optimize molecules with both continuous coordinates and discrete types against protein targets. A promising direction is to exert gradient guidance on generative models given its remarkable success in images, but it is challenging to guide discrete data and risks inconsistencies between modalities. To this end, we leverage a continuous and differentiable space derived through Bayesian inference, presenting Molecule Joint Optimization (MolJO), the first gradient-based SBMO framework that facilitates joint guidance signals across different modalities while preserving SE(3)-equivariance. We introduce a novel backward correction strategy that optimizes within a sliding window of the past histories, allowing for a seamless trade-off between explore-and-exploit during optimization. Our proposed MolJO achieves state-of-the-art performance on CrossDocked2020 benchmark (Success Rate 51.3% , Vina Dock -9.05 and SA 0.78), more than 4x improvement in Success Rate compared to the gradient-based counterpart, and 2x "Me-Better" Ratio as much as 3D baselines. Furthermore, we extend MolJO to a wide range of optimization settings, including multi-objective optimization and challenging tasks in drug design such as R-group optimization and scaffold hopping, further underscoring its versatility and potential.